Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $712,000.

  • Avidity Biosciences' Capital Expenditures fell 58.22% to $712,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year increase of 192.15%. This contributed to the annual value of $7.1 million for FY2024, which is 67.12% up from last year.
  • As of Q3 2025, Avidity Biosciences' Capital Expenditures stood at $712,000, which was down 78.70% from $3.3 million recorded in Q2 2025.
  • Avidity Biosciences' 5-year Capital Expenditures high stood at $3.9 million for Q4 2024, and its period low was -$107,000 during Q3 2022.
  • In the last 3 years, Avidity Biosciences' Capital Expenditures had a median value of $923,000 in 2023 and averaged $1.7 million.
  • In the last 5 years, Avidity Biosciences' Capital Expenditures surged by 5,150.00% in 2021 and then slumped by 113.38% in 2022.
  • Over the past 5 years, Avidity Biosciences' Capital Expenditures (Quarterly) stood at $1.7 million in 2021, then plummeted by 50.21% to $850,000 in 2022, then rose by 1.53% to $863,000 in 2023, then soared by 353.77% to $3.9 million in 2024, then crashed by 58.22% to $712,000 in 2025.
  • Its last three reported values are $712,000 in Q3 2025, $3.3 million for Q2 2025, and $3.8 million during Q1 2025.